Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1B Study of Donafenib Monotherapy for Previously Treated Metastatic Gastric Cancer

NCT02489214 is registered in ClinicalTrials.gov with Suzhou Zelgen Biopharmaceuticals Co.,Ltd as lead sponsor.

NCT NCT02489214
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02489214 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1B Study of Donafenib Monotherapy for Previously Treated Metastatic Gastric Cancer
Lead sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase
Phase 1/2
Overall status
Terminated
Start date
May 16, 2016
Completion date
June 13, 2019
Enrollment
13 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer